WO2011129792A1 - Water dispersible formulations comprising cefpodoxime proxetil - Google Patents
Water dispersible formulations comprising cefpodoxime proxetil Download PDFInfo
- Publication number
- WO2011129792A1 WO2011129792A1 PCT/TR2011/000092 TR2011000092W WO2011129792A1 WO 2011129792 A1 WO2011129792 A1 WO 2011129792A1 TR 2011000092 W TR2011000092 W TR 2011000092W WO 2011129792 A1 WO2011129792 A1 WO 2011129792A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical composition
- composition according
- agent
- cellulose
- sodium
- Prior art date
Links
- LTINZAODLRIQIX-FBXRGJNPSA-N cefpodoxime proxetil Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC)C(=O)OC(C)OC(=O)OC(C)C)C(=O)C(=N/OC)\C1=CSC(N)=N1 LTINZAODLRIQIX-FBXRGJNPSA-N 0.000 title claims abstract description 43
- 229960004797 cefpodoxime proxetil Drugs 0.000 title claims abstract description 43
- 239000000203 mixture Substances 0.000 title claims description 54
- 238000009472 formulation Methods 0.000 title description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 34
- 239000003795 chemical substances by application Substances 0.000 claims description 59
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 24
- 239000004562 water dispersible granule Substances 0.000 claims description 21
- 239000004565 water dispersible tablet Substances 0.000 claims description 19
- 239000003085 diluting agent Substances 0.000 claims description 17
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 15
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 15
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 15
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 15
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 claims description 13
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 claims description 13
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 claims description 13
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 12
- 230000002378 acidificating effect Effects 0.000 claims description 12
- 229940071676 hydroxypropylcellulose Drugs 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- 235000002639 sodium chloride Nutrition 0.000 claims description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 10
- 239000000314 lubricant Substances 0.000 claims description 10
- 230000001105 regulatory effect Effects 0.000 claims description 10
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 8
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 8
- 239000011230 binding agent Substances 0.000 claims description 8
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 8
- 235000015165 citric acid Nutrition 0.000 claims description 8
- 239000007884 disintegrant Substances 0.000 claims description 8
- 239000003826 tablet Substances 0.000 claims description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 6
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- 229920002472 Starch Polymers 0.000 claims description 6
- 239000000796 flavoring agent Substances 0.000 claims description 6
- 235000013355 food flavoring agent Nutrition 0.000 claims description 6
- 239000008101 lactose Substances 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 6
- 239000011780 sodium chloride Substances 0.000 claims description 6
- 239000008107 starch Substances 0.000 claims description 6
- 235000019698 starch Nutrition 0.000 claims description 6
- 239000013543 active substance Substances 0.000 claims description 5
- 235000010980 cellulose Nutrition 0.000 claims description 5
- 229920002678 cellulose Polymers 0.000 claims description 5
- 239000001913 cellulose Substances 0.000 claims description 5
- 238000005469 granulation Methods 0.000 claims description 5
- 230000003179 granulation Effects 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 239000000377 silicon dioxide Substances 0.000 claims description 5
- 235000012239 silicon dioxide Nutrition 0.000 claims description 5
- 239000000454 talc Substances 0.000 claims description 5
- 229910052623 talc Inorganic materials 0.000 claims description 5
- 235000012222 talc Nutrition 0.000 claims description 5
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- 108010011485 Aspartame Proteins 0.000 claims description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 4
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 4
- 239000001856 Ethyl cellulose Substances 0.000 claims description 4
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 4
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 4
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 claims description 4
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 4
- 239000000605 aspartame Substances 0.000 claims description 4
- 235000010357 aspartame Nutrition 0.000 claims description 4
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 4
- 229960003438 aspartame Drugs 0.000 claims description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 4
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 4
- 235000010216 calcium carbonate Nutrition 0.000 claims description 4
- 239000001175 calcium sulphate Substances 0.000 claims description 4
- 235000011132 calcium sulphate Nutrition 0.000 claims description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 4
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 4
- 229920001249 ethyl cellulose Polymers 0.000 claims description 4
- 229960001031 glucose Drugs 0.000 claims description 4
- 150000004677 hydrates Chemical class 0.000 claims description 4
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 4
- 229940071826 hydroxyethyl cellulose Drugs 0.000 claims description 4
- 229920003063 hydroxymethyl cellulose Polymers 0.000 claims description 4
- 229940031574 hydroxymethyl cellulose Drugs 0.000 claims description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 4
- 229960003943 hypromellose Drugs 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 4
- 239000001630 malic acid Substances 0.000 claims description 4
- 235000011090 malic acid Nutrition 0.000 claims description 4
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 4
- 229920000609 methyl cellulose Polymers 0.000 claims description 4
- 239000001923 methylcellulose Substances 0.000 claims description 4
- 235000010981 methylcellulose Nutrition 0.000 claims description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 4
- 235000015497 potassium bicarbonate Nutrition 0.000 claims description 4
- 229910000028 potassium bicarbonate Inorganic materials 0.000 claims description 4
- 239000011736 potassium bicarbonate Substances 0.000 claims description 4
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims description 4
- 229940069328 povidone Drugs 0.000 claims description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 4
- 235000017550 sodium carbonate Nutrition 0.000 claims description 4
- 239000012453 solvate Substances 0.000 claims description 4
- 235000010356 sorbitol Nutrition 0.000 claims description 4
- 239000000600 sorbitol Substances 0.000 claims description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 4
- 239000011975 tartaric acid Substances 0.000 claims description 4
- 235000002906 tartaric acid Nutrition 0.000 claims description 4
- 235000019731 tricalcium phosphate Nutrition 0.000 claims description 4
- 239000000811 xylitol Substances 0.000 claims description 4
- 235000010447 xylitol Nutrition 0.000 claims description 4
- 229960002675 xylitol Drugs 0.000 claims description 4
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 4
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 3
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 3
- -1 glidant Substances 0.000 claims description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 3
- 235000011181 potassium carbonates Nutrition 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 239000004475 Arginine Substances 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 2
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- 229930091371 Fructose Natural products 0.000 claims description 2
- 239000005715 Fructose Substances 0.000 claims description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 2
- 239000001828 Gelatine Substances 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- 239000005913 Maltodextrin Substances 0.000 claims description 2
- 229920002774 Maltodextrin Polymers 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 239000008118 PEG 6000 Substances 0.000 claims description 2
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- 239000004376 Sucralose Substances 0.000 claims description 2
- YGCFIWIQZPHFLU-UHFFFAOYSA-N acesulfame Chemical compound CC1=CC(=O)NS(=O)(=O)O1 YGCFIWIQZPHFLU-UHFFFAOYSA-N 0.000 claims description 2
- 229960005164 acesulfame Drugs 0.000 claims description 2
- 235000011054 acetic acid Nutrition 0.000 claims description 2
- 239000001361 adipic acid Substances 0.000 claims description 2
- 235000011037 adipic acid Nutrition 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- 235000010323 ascorbic acid Nutrition 0.000 claims description 2
- 239000011668 ascorbic acid Substances 0.000 claims description 2
- 229960005070 ascorbic acid Drugs 0.000 claims description 2
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 claims description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims description 2
- 235000013539 calcium stearate Nutrition 0.000 claims description 2
- 239000008116 calcium stearate Substances 0.000 claims description 2
- OCHFNTLZOZPXFE-JEDNCBNOSA-N carbonic acid;(2s)-2,6-diaminohexanoic acid Chemical compound OC(O)=O.NCCCC[C@H](N)C(O)=O OCHFNTLZOZPXFE-JEDNCBNOSA-N 0.000 claims description 2
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 2
- 229960000913 crospovidone Drugs 0.000 claims description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 2
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 claims description 2
- 239000008121 dextrose Substances 0.000 claims description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 2
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 claims description 2
- RRPFCKLVOUENJB-UHFFFAOYSA-L disodium;2-aminoacetic acid;carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O.NCC(O)=O RRPFCKLVOUENJB-UHFFFAOYSA-L 0.000 claims description 2
- 238000007908 dry granulation Methods 0.000 claims description 2
- 229960004667 ethyl cellulose Drugs 0.000 claims description 2
- 229960002737 fructose Drugs 0.000 claims description 2
- 239000001530 fumaric acid Substances 0.000 claims description 2
- 235000011087 fumaric acid Nutrition 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 235000001727 glucose Nutrition 0.000 claims description 2
- 229940093915 gynecological organic acid Drugs 0.000 claims description 2
- 239000003906 humectant Substances 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- 239000000832 lactitol Substances 0.000 claims description 2
- 235000010448 lactitol Nutrition 0.000 claims description 2
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 claims description 2
- 229960003451 lactitol Drugs 0.000 claims description 2
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims description 2
- 239000001095 magnesium carbonate Substances 0.000 claims description 2
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims description 2
- 239000000395 magnesium oxide Substances 0.000 claims description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 2
- 235000019359 magnesium stearate Nutrition 0.000 claims description 2
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims description 2
- 239000000845 maltitol Substances 0.000 claims description 2
- 235000010449 maltitol Nutrition 0.000 claims description 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims description 2
- 229940035436 maltitol Drugs 0.000 claims description 2
- 229940035034 maltodextrin Drugs 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 229960002900 methylcellulose Drugs 0.000 claims description 2
- 150000007524 organic acids Chemical class 0.000 claims description 2
- 235000005985 organic acids Nutrition 0.000 claims description 2
- 235000011007 phosphoric acid Nutrition 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims description 2
- 239000004300 potassium benzoate Substances 0.000 claims description 2
- 235000010235 potassium benzoate Nutrition 0.000 claims description 2
- 229940103091 potassium benzoate Drugs 0.000 claims description 2
- 239000001103 potassium chloride Substances 0.000 claims description 2
- 235000011164 potassium chloride Nutrition 0.000 claims description 2
- 229960002816 potassium chloride Drugs 0.000 claims description 2
- 239000001508 potassium citrate Substances 0.000 claims description 2
- 229960002635 potassium citrate Drugs 0.000 claims description 2
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 claims description 2
- 235000011082 potassium citrates Nutrition 0.000 claims description 2
- 235000011118 potassium hydroxide Nutrition 0.000 claims description 2
- 235000019260 propionic acid Nutrition 0.000 claims description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 2
- 229960001866 silicon dioxide Drugs 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 2
- 239000004299 sodium benzoate Substances 0.000 claims description 2
- 235000010234 sodium benzoate Nutrition 0.000 claims description 2
- 229960001462 sodium cyclamate Drugs 0.000 claims description 2
- 229960002920 sorbitol Drugs 0.000 claims description 2
- 239000001384 succinic acid Substances 0.000 claims description 2
- 235000011044 succinic acid Nutrition 0.000 claims description 2
- 235000019408 sucralose Nutrition 0.000 claims description 2
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 2
- 238000005550 wet granulation Methods 0.000 claims description 2
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims 2
- 229960002668 sodium chloride Drugs 0.000 claims 2
- 229960004793 sucrose Drugs 0.000 claims 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 claims 1
- 239000013078 crystal Substances 0.000 claims 1
- 235000013681 dietary sucrose Nutrition 0.000 claims 1
- 239000011777 magnesium Substances 0.000 claims 1
- 229910052749 magnesium Inorganic materials 0.000 claims 1
- 235000001055 magnesium Nutrition 0.000 claims 1
- 229940091250 magnesium supplement Drugs 0.000 claims 1
- 229940086066 potassium hydrogencarbonate Drugs 0.000 claims 1
- 229960005090 cefpodoxime Drugs 0.000 description 6
- WYUSVOMTXWRGEK-HBWVYFAYSA-N cefpodoxime Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC)C(O)=O)C(=O)C(=N/OC)\C1=CSC(N)=N1 WYUSVOMTXWRGEK-HBWVYFAYSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- 201000003146 cystitis Diseases 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 206010024971 Lower respiratory tract infections Diseases 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 201000005661 acute cystitis Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- NHSCRWJPZDNMBU-UHFFFAOYSA-L dipotassium carbonic acid carbonate Chemical compound [K+].[K+].OC([O-])=O.OC([O-])=O NHSCRWJPZDNMBU-UHFFFAOYSA-L 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- ZADYMNAVLSWLEQ-UHFFFAOYSA-N magnesium;oxygen(2-);silicon(4+) Chemical compound [O-2].[O-2].[O-2].[Mg+2].[Si+4] ZADYMNAVLSWLEQ-UHFFFAOYSA-N 0.000 description 1
- 229960002160 maltose Drugs 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229940100692 oral suspension Drugs 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 229950000033 proxetil Drugs 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
Definitions
- the present invention relates to pharmaceutical formulations comprising cefpodoxime proxetil.
- Background of the invention :
- Cefpodoxime proxetil (figure 1), which has the chemical name pivaloyloxymethyl 7-[2-(2- amino-thiazol-4-yl] -2-(syn)-memoxyimino-acetamido] -3 -methoxymethyl-3 -cephem-4- carboxylate, was first disclosed in the patent numbered EP0049118.
- Cefpodoxime is a third generation cephalosporin and for that reason, it is indicated for use in the treatment of infections caused by gram positive and gram negative bacteria.
- Cefpodoxime proxetil is available in oral tablet and oral suspension forms on the market. Cefpodoxime proxetil is a molecule which has a very low solubility in water. Therefore, oral bioavailability of the tablet form is 50% less than cefpodoxime given intravenously.
- Cefpodoxime proxetil is a hydrophobic molecule and has a water contact angle greater than 90°. Therefore, cefpodoxime proxetil has a low solubility and when used in a pharmaceutical composition has poor disintegration in water.
- Patent application numbered in WO/2002/067943 relates to pharmaceutical compositions which are suitable for oral use and which comprise cefpodoxime proxetil and pharmaceutical carrier which cefpodoxime is adsorbed on. Said patent application aims to solve the low solubility and slow dispersion of cefpodoxime proxetil.
- cefpodoxime proxetil exhibits gel formation and forms a gelatinous mass when in contact with aqueous media. Therefore, the gel formation results in poor disintegration and slow dissolution and hence absorption of cefpodoxime from the gastro-intestinal tract and its bioavailability is greatly reduced.
- the subject matter of the present invention is related to water dispersible tablet and granule formulations comprising cefpodoxime proxetil.
- the present invention relates to the formulation and preparation procedures of these products.
- cellulose- based viscosity agent is used and the ratio of viscosity agent: diluent used in the formulation is in the range of 1:5 and 1:10, it is surprisingly observed that water dispersible tablet and granule formulations comprising cefpodoxime proxetil do not exhibit gel formation, dissolve in water entirely and provide high absorption and thus bio-availability of cefpodoxime proxetil.
- the first aspect of the present invention is that said water dispersible tablet and granule formulations comprising cefpodoxime proxetil comprise cellulosed based viscosity agent and diluent in an amount such that viscosity agent: diluent ratio is in the range of 1 :5 and 1:10.
- excipients selected from, but not limited to, a group comprising binders, glidants, lubricants, humectants, disintegrants, diluents, basic agents, acidic agents, taste regulating agents, viscosity agents, flavoring agents and optionally effervescent couple can be used in water dispersible tablet and granule formulations in addition to cefpodoxime proxetil.
- the cellulose-based viscosity agent that can be used in water dispersible tablet and granule formulations of the present invention can be selected from, but not limited to, a group comprising carboxymethyl cellulose sodium, carboxymethyl cellulose calcium, ethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxymethyl cellulose, hypromellose or combinations thereof.
- viscosity agent is selected from hydroxypropyl cellulose, carboxymethyl cellulose sodium, carboxymethyl cellulose calcium or a binary/ternary combination thereof. More preferably a combination of hydroxypropyl cellulose, carboxymethyl cellulose sodium, and carboxymethyl cellulose calcium is used in the formulations pertaining to the present invention.
- hydroxypropyl cellulose: carboxymethyl cellulose sodium: carboxymethyl cellulose calcium ratio is an important criteria for the solubility of cefpodoxime proxetil and the dissolution of the formulation comprising cefpodoxime proxetil.
- hydroxypropyl cellulose: carboxymethyl cellulose sodium: carboxymethyl cellulose calcium ratio is in the range of 1: 1: 1 and 1: 8: 9, preferably 1: 2: 3 and 1: 6: 8 and more preferably 1: 3: 4 and 1: 5: 6, the formulation comprising cefpodoxime proxetil pertaining to the present invention has dispersed entirely and formed a homogeneous solution.
- a viscosity agent mixture comprising hydroxypropyl cellulose, carboxymethyl cellulose sodium and carboxymethyl cellulose calcium in an amount such that hydroxypropyl cellulose : carboxymethyl cellulose sodium : carboxymethyl cellulose calcium ratio is in the range of 1 : 1: 1 and 1 : 8: 9, preferably 1 : 2: 3 and 1: 6: 8 and more preferably 1: 3: 4 and 1 : 5: 6 is used.
- the diluent that can be used in water dispersible tablet and granule formulations of the present invention can be selected from, but not limited to, a group comprising calcium carbonate, calcium sulphate, dibasic calcium phosphate, tribasic calcium phosphate, calcium phosphate, calcium sulphate, microcrystalline cellulose, lactose, magnesium carbonate, magnesium oxide, maltodextrin, maltose, mannitol, sodium chloride, sorbitol, starch and xylitol or combinations thereof.
- lactose is used as the diluent in the formulations pertaining to the present invention.
- said water dispersible tablet and granule formulations wherein cefpodoxime proxetil is used as an active agent comprise a combination of hydroxypropyl cellulose, carboxymethyl cellulose sodium and carboxymethyl cellulose calcium as viscosity agent mixture and lactose as diluent in an amount such that viscosity agent mixture: lactose ratio is in the range of 1 :5 and 1:10.
- the binder that can be used in water dispersible tablet and granule formulations of the present invention can be selected from, but not limited to, a group comprising ethyl cellulose, gelatine, hydroxyethyl cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, hypromellose, magnesium aluminum silicate, methyl cellulose, povidone or combinations thereof.
- the lubricant that can be used in water dispersible tablet and granule formulations of the present invention can be selected from, but not limited to, a group comprising calcium stearate, magnesium stearate, polyethylene glycol, PEG 6000, polyvinyl alcohol, potassium benzoate, talc, sodium benzoate or a combination thereof.
- talc is used as the lubricant in the formulations pertaining to the present invention.
- the glidant that can be used in water dispersible tablet and granule formulations of the present invention can be selected from, but not limited to, a group comprising magnesium silicate, silicon dioxide, starch, talc, tribasic calcium phosphate or a combination thereof.
- silicon dioxide is used as the glidant in the formulations pertaining to the present invention.
- the disintegrant that can be used in water dispersible tablet and granule formulations of the present invention can be selected from, but not limited to, a group comprising carboxymethyl cellulose calcium, carboxymethyl cellulose sodium, microcrystalline cellulose, silicon dioxide, croscarmellose sodium, crospovidone, hydroxypropyl cellulose, methyl cellulose, povidone, magnesium aluminum silicate and starch or combinations thereof.
- the taste regulating agent that can be used in water dispersible tablet and granule formulations of the present invention can be selected from, but not limited to, a group comprising acesulfame, aspartame, dextrose, fructose, glucose, lactitol, maltitol, maltose, sorbitol, saccharine, saccharine sodium, sodium cyclamate, sucralose, sodium chloride, potassium chloride, sucrose, xylitol or combinations thereof.
- sucrose, aspartame, sodium chloride or a combination thereof is used in the formulations according to the present invention.
- the basic agent that can be used in water dispersible tablet and granule formulations of the present invention can be selected from, but not limited to, a group comprising potassium carbonate, potassium bicarbonate, potassium citrate, potassium hydroxide, sodium carbonate, sodium bicarbonate or combinations thereof.
- the acidic agent that can be used in water dispersible tablet and granule formulations of the present invention can be selected from, but not limited to, a group comprising acetic acid, citric acid, lactic acid, malic acid, phosphoric acid, propionic acid, tartaric acid or combinations thereof.
- citric acid is used as the acidic agent in the formulations prepared according to the present invention.
- Effervescent acid used in the present invention can be selected from organic acids such as citric acid, tartaric acid, malic acid, fumaric acid, ascorbic acid, adipic acid and succinic acid. Citric acid is preferably used.
- Effervescent base used in the present invention can be selected from basic agents such as sodium hydrogen carbonate, sodium carbonate, potassium carbonate potassium hydrogen carbonate, sodium glycine carbonate, lysine carbonate, arginine carbonate and calcium carbonate. Sodium hydrogen carbonate is preferably used.
- cefpodoxime proxetil in water dispersible tablet and granule formulation of the present invention, cefpodoxime proxetil can be used in the form of its pharmaceutically acceptable salts, hydrates, solvates or combinations thereof.
- the water dispersible tablet and granule formulation of the present invention can contain 5- 50% cefpodoxime proxetil or its pharmaceutically acceptable salts, hydrates, solvates or combinations thereof with respect to the total amount of unit dose.
- the water dispersible tablet and granule formulation of the present invention can comprise 5- 50% cefpodoxime proxetil, 0-30% binder, 0.5-4% glidant, 1-7% lubricant, 0-15% disintegrant and or disintegrants, 1-65% diluent, 1-25% taste regulating agent, 0-20% basic agent, 0.1- 25% acidic agent, 2-15% viscosity agent and/or viscosity agents, 0.1-3% flavoring agents and 0-80% effervescent couple with respect to the total amount of unit dose.
- the total amount of one or more viscosity agents contained water dispersible formulation of the present invention is in the range of 2-15%, preferably in the range of 5- 12%, more preferably in the range of 7-10 %.
- the ratio of acidic agent to cefpodoxime proxetil that is used as active agent is in the range of 1:2 to 1:15 in water dispersible formulations according to the present invention. It has been seen that the solubility of the formulation in water has increased upon using acidic agent in the amount specified above.
- the present invention relates to processes which can be used for the preparation of water dispersible formulations that are suitable for use as single dose and that comprise pharmaceutically acceptable excipients in addition to cefpodoxime proxetil that is used as active agent.
- the process of the present invention comprises the granulation of cefpodoxime proxetil through conventional wet and/or dry granulation methods; or dry blending of cefpodoxime proxetil and other excipients to obtain powder and optionally compressing the obtained powder in tablet form.
- the water dispersible pharmaceutical formulation prepared according to the invention is used for the treatment of the diseases relative to the upper respiratory tract infections such as pharangitis, tonsillitis, otitis media; lower respiratory tract infections such as acute pneumonia, acute and chronic broncihia and urinary tract infections such as acute cystitis and cystourethritis.
- upper respiratory tract infections such as pharangitis, tonsillitis, otitis media
- lower respiratory tract infections such as acute pneumonia, acute and chronic broncihia
- urinary tract infections such as acute cystitis and cystourethritis.
- Water dispersible formulations according to present invention can be prepared according to the examples given below. The examples are given for demonstration of the invention and the invention cannot be limited to these.
- EXAMPLE 1 Formulation and process for the preparation of water dispersible granules
- a process for preparation of water dispersible granule given in the example comprises dissolving cefpodoxime proxetil in a suitable solvent and granulation of the diluent and taste regulating agent with this solution and then drying these granules and mixing them with viscosity agent, lubricant, glidant and acidic agent.
- EXAMPLE 2 Formulation and process for the preparation of effervescent tablet
- Flavoring agent 1.5% The formulation to be used in scope of the present invention can be obtained by granulation of the effervescent couple, taste regulating agent and the binder with the granulation solution comprising diluent. The granules are then dried and mixed with cefpodoxime proxetil. Following this, the flavoring agent, viscosity agent and the lubricant are added to the blend. The obtained mixture is then compressed in tablet compressing machine to obtain tablets.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Cephalosporin Compounds (AREA)
Abstract
The present invention relates to pharmaceutical formulations comprising cefpodoxime proxetil.
Description
WATER DISPERSIBLE FORMULATIONS COMPRISING CEFPODOXIME
PROXETIL
The present invention relates to pharmaceutical formulations comprising cefpodoxime proxetil. Background of the invention:
Cefpodoxime proxetil (figure 1), which has the chemical name pivaloyloxymethyl 7-[2-(2- amino-thiazol-4-yl] -2-(syn)-memoxyimino-acetamido] -3 -methoxymethyl-3 -cephem-4- carboxylate, was first disclosed in the patent numbered EP0049118.
Cefpodoxime is a third generation cephalosporin and for that reason, it is indicated for use in the treatment of infections caused by gram positive and gram negative bacteria.
Cefpodoxime proxetil is available in oral tablet and oral suspension forms on the market. Cefpodoxime proxetil is a molecule which has a very low solubility in water. Therefore, oral bioavailability of the tablet form is 50% less than cefpodoxime given intravenously.
Tablets which contain 100 mg and 200 mg of cefpodoxime are available on the market. When these tablets containing 100 or 200 mg of active agent are formulated with excipients, they become too large in size and this makes the use of this dosage form inconvenient for patients who have swallowing difficulties, especially for pediatric and geriatric patients. Alternatively, the use of reliable and user-friendly water dispersible forms is suggested.
Cefpodoxime proxetil is a hydrophobic molecule and has a water contact angle greater than 90°. Therefore, cefpodoxime proxetil has a low solubility and when used in a pharmaceutical composition has poor disintegration in water.
In the prior art, several methods have been developed in order to solve the solubility problem of cefpodoxime proxetil in water and increase the disintegration rate and thus absorption of it. Patent application numbered in WO/2002/067943 relates to pharmaceutical compositions which are suitable for oral use and which comprise cefpodoxime proxetil and pharmaceutical carrier which cefpodoxime is adsorbed on. Said patent application aims to solve the low solubility and slow dispersion of cefpodoxime proxetil. However, in these alternatively developed formulations comprising cefpodoxime proxetil in the prior art, solubility problem has been tried to be solved to some extent but it has been observed that cefpodoxime proxetil exhibits gel formation and forms a gelatinous mass when in contact with aqueous media. Therefore, the gel formation results in poor disintegration and slow dissolution and hence absorption of cefpodoxime from the gastro-intestinal tract and its bioavailability is greatly reduced.
As it is seen, new formulations are required to be developed to overcome the solubility and gelling problems of cefpodoxime proxetil and obtain new drugs, which can dissolve quickly in water, which do not exhibit gel formation in water and which can be easily absorbed in the gastro-intestinal tract. The inventors have surprisingly obtained water dispersible tablet and granule formulations comprising cefpodoxime proxetil which overcome the problems that are encountered in the prior art , in other words which can easily dissolve, which can disperse completely and which does not show gelling behavior when dispersed in water.
Description of the invention: The subject matter of the present invention is related to water dispersible tablet and granule formulations comprising cefpodoxime proxetil. In another aspect, the present invention relates to the formulation and preparation procedures of these products. In cases where cellulose- based viscosity agent is used and the ratio of viscosity agent: diluent used in the formulation is in the range of 1:5 and 1:10, it is surprisingly observed that water dispersible tablet and granule formulations comprising cefpodoxime proxetil do not exhibit gel formation, dissolve
in water entirely and provide high absorption and thus bio-availability of cefpodoxime proxetil.
Accordingly, the first aspect of the present invention is that said water dispersible tablet and granule formulations comprising cefpodoxime proxetil comprise cellulosed based viscosity agent and diluent in an amount such that viscosity agent: diluent ratio is in the range of 1 :5 and 1:10.
Various excipients selected from, but not limited to, a group comprising binders, glidants, lubricants, humectants, disintegrants, diluents, basic agents, acidic agents, taste regulating agents, viscosity agents, flavoring agents and optionally effervescent couple can be used in water dispersible tablet and granule formulations in addition to cefpodoxime proxetil.
The cellulose-based viscosity agent that can be used in water dispersible tablet and granule formulations of the present invention can be selected from, but not limited to, a group comprising carboxymethyl cellulose sodium, carboxymethyl cellulose calcium, ethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxymethyl cellulose, hypromellose or combinations thereof. Preferably, viscosity agent is selected from hydroxypropyl cellulose, carboxymethyl cellulose sodium, carboxymethyl cellulose calcium or a binary/ternary combination thereof. More preferably a combination of hydroxypropyl cellulose, carboxymethyl cellulose sodium, and carboxymethyl cellulose calcium is used in the formulations pertaining to the present invention. The inventors have found that hydroxypropyl cellulose: carboxymethyl cellulose sodium: carboxymethyl cellulose calcium ratio is an important criteria for the solubility of cefpodoxime proxetil and the dissolution of the formulation comprising cefpodoxime proxetil. In cases where hydroxypropyl cellulose: carboxymethyl cellulose sodium: carboxymethyl cellulose calcium ratio is in the range of 1: 1: 1 and 1: 8: 9, preferably 1: 2: 3 and 1: 6: 8 and more preferably 1: 3: 4 and 1: 5: 6, the formulation comprising cefpodoxime proxetil pertaining to the present invention has dispersed entirely and formed a homogeneous solution.
According to this, another aspect of the present invention is that a viscosity agent mixture comprising hydroxypropyl cellulose, carboxymethyl cellulose sodium and carboxymethyl cellulose calcium in an amount such that hydroxypropyl cellulose : carboxymethyl cellulose sodium : carboxymethyl cellulose calcium ratio is in the range of 1 : 1: 1 and 1 : 8: 9, preferably 1 : 2: 3 and 1: 6: 8 and more preferably 1: 3: 4 and 1 : 5: 6 is used.
The diluent that can be used in water dispersible tablet and granule formulations of the present invention can be selected from, but not limited to, a group comprising calcium carbonate, calcium sulphate, dibasic calcium phosphate, tribasic calcium phosphate, calcium phosphate, calcium sulphate, microcrystalline cellulose, lactose, magnesium carbonate, magnesium oxide, maltodextrin, maltose, mannitol, sodium chloride, sorbitol, starch and xylitol or combinations thereof. Preferably, lactose is used as the diluent in the formulations pertaining to the present invention.
Accordingly, another aspect of the present invention is that said water dispersible tablet and granule formulations wherein cefpodoxime proxetil is used as an active agent comprise a combination of hydroxypropyl cellulose, carboxymethyl cellulose sodium and carboxymethyl cellulose calcium as viscosity agent mixture and lactose as diluent in an amount such that viscosity agent mixture: lactose ratio is in the range of 1 :5 and 1:10.
The binder that can be used in water dispersible tablet and granule formulations of the present invention can be selected from, but not limited to, a group comprising ethyl cellulose, gelatine, hydroxyethyl cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, hypromellose, magnesium aluminum silicate, methyl cellulose, povidone or combinations thereof.
The lubricant that can be used in water dispersible tablet and granule formulations of the present invention can be selected from, but not limited to, a group comprising calcium stearate, magnesium stearate, polyethylene glycol, PEG 6000, polyvinyl alcohol, potassium benzoate, talc, sodium benzoate or a combination thereof. Preferably, talc is used as the lubricant in the formulations pertaining to the present invention.
The glidant that can be used in water dispersible tablet and granule formulations of the present invention can be selected from, but not limited to, a group comprising magnesium silicate, silicon dioxide, starch, talc, tribasic calcium phosphate or a combination thereof. Preferably, silicon dioxide is used as the glidant in the formulations pertaining to the present invention.
The disintegrant that can be used in water dispersible tablet and granule formulations of the present invention can be selected from, but not limited to, a group comprising carboxymethyl cellulose calcium, carboxymethyl cellulose sodium, microcrystalline cellulose, silicon dioxide, croscarmellose sodium, crospovidone, hydroxypropyl cellulose, methyl cellulose, povidone, magnesium aluminum silicate and starch or combinations thereof.
The taste regulating agent that can be used in water dispersible tablet and granule formulations of the present invention can be selected from, but not limited to, a group comprising acesulfame, aspartame, dextrose, fructose, glucose, lactitol, maltitol, maltose, sorbitol, saccharine, saccharine sodium, sodium cyclamate, sucralose, sodium chloride, potassium chloride, sucrose, xylitol or combinations thereof. Preferably, sucrose, aspartame, sodium chloride or a combination thereof is used in the formulations according to the present invention.
The basic agent that can be used in water dispersible tablet and granule formulations of the present invention can be selected from, but not limited to, a group comprising potassium carbonate, potassium bicarbonate, potassium citrate, potassium hydroxide, sodium carbonate, sodium bicarbonate or combinations thereof.
The acidic agent that can be used in water dispersible tablet and granule formulations of the present invention can be selected from, but not limited to, a group comprising acetic acid, citric acid, lactic acid, malic acid, phosphoric acid, propionic acid, tartaric acid or combinations thereof. Preferably, citric acid is used as the acidic agent in the formulations prepared according to the present invention.
Effervescent acid used in the present invention can be selected from organic acids such as citric acid, tartaric acid, malic acid, fumaric acid, ascorbic acid, adipic acid and succinic acid. Citric acid is preferably used. Effervescent base used in the present invention can be selected from basic agents such as sodium hydrogen carbonate, sodium carbonate, potassium carbonate potassium hydrogen carbonate, sodium glycine carbonate, lysine carbonate, arginine carbonate and calcium carbonate. Sodium hydrogen carbonate is preferably used.
In water dispersible tablet and granule formulation of the present invention, cefpodoxime proxetil can be used in the form of its pharmaceutically acceptable salts, hydrates, solvates or combinations thereof.
The water dispersible tablet and granule formulation of the present invention can contain 5- 50% cefpodoxime proxetil or its pharmaceutically acceptable salts, hydrates, solvates or combinations thereof with respect to the total amount of unit dose.
The water dispersible tablet and granule formulation of the present invention can comprise 5- 50% cefpodoxime proxetil, 0-30% binder, 0.5-4% glidant, 1-7% lubricant, 0-15% disintegrant and or disintegrants, 1-65% diluent, 1-25% taste regulating agent, 0-20% basic agent, 0.1- 25% acidic agent, 2-15% viscosity agent and/or viscosity agents, 0.1-3% flavoring agents and 0-80% effervescent couple with respect to the total amount of unit dose.
In another aspect, the total amount of one or more viscosity agents contained water dispersible formulation of the present invention is in the range of 2-15%, preferably in the range of 5- 12%, more preferably in the range of 7-10 %.
In another aspect, the ratio of acidic agent to cefpodoxime proxetil that is used as active agent is in the range of 1:2 to 1:15 in water dispersible formulations according to the present invention. It has been seen that the solubility of the formulation in water has increased upon using acidic agent in the amount specified above.
In another aspect, the present invention relates to processes which can be used for the preparation of water dispersible formulations that are suitable for use as single dose and that comprise pharmaceutically acceptable excipients in addition to cefpodoxime proxetil that is used as active agent.
Accordingly, the process of the present invention comprises the granulation of cefpodoxime proxetil through conventional wet and/or dry granulation methods; or dry blending of cefpodoxime proxetil and other excipients to obtain powder and optionally compressing the obtained powder in tablet form.
Another aspect of the present invention is that the water dispersible pharmaceutical formulation prepared according to the invention is used for the treatment of the diseases relative to the upper respiratory tract infections such as pharangitis, tonsillitis, otitis media; lower respiratory tract infections such as acute pneumonia, acute and chronic broncihia and urinary tract infections such as acute cystitis and cystourethritis.
Water dispersible formulations according to present invention can be prepared according to the examples given below. The examples are given for demonstration of the invention and the invention cannot be limited to these.
EXAMPLE 1 : Formulation and process for the preparation of water dispersible granules
A process for preparation of water dispersible granule given in the example comprises dissolving cefpodoxime proxetil in a suitable solvent and granulation of the diluent and taste regulating agent with this solution and then drying these granules and mixing them with viscosity agent, lubricant, glidant and acidic agent.
EXAMPLE 2: Formulation and process for the preparation of effervescent tablet
% of amount present in unit dose
Cefpodoxime proxetil 13.5%
Effervescent acid 33%
Effervescent Base 31%
Binder 1%
Diluent 14 %
Viscosity agent 2.5%
Taste regulating agent 1.5%
Lubricant 2.0%
Flavoring agent 1.5%
The formulation to be used in scope of the present invention can be obtained by granulation of the effervescent couple, taste regulating agent and the binder with the granulation solution comprising diluent. The granules are then dried and mixed with cefpodoxime proxetil. Following this, the flavoring agent, viscosity agent and the lubricant are added to the blend. The obtained mixture is then compressed in tablet compressing machine to obtain tablets.
Claims
1. A pharmaceutical composition formulated in water dispersible tablet and granule form comprising cefpodoxime proxetil characterized in that in said composition viscosity agent is cellulose-based and the ratio of viscosity agent to diluent is in the range of 1:5 to 1 :10.
2. The pharmaceutical composition according to claim 1, wherein cefpodoxime proxetil that is used as the active agent can be in the form of its pharmaceutically acceptable salts, hydrates, solvates or combinations thereof.
3. The pharmaceutical composition according to claim 1, wherein the cellulose-based viscosity agent is selected from a group comprising carboxymethyl cellulose sodium, carboxymethyl cellulose calcium, ethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxymethyl cellulose, hypromellose or combinations thereof.
4. The pharmaceutical composition according to claim 3, wherein cellulose-based viscosity agent is selected from a group comprising hydroxypropyl cellulose, carboxymethyl cellulose sodium, carboxymethyl cellulose calcium and binary/ternary combinations thereof.
5. The pharmaceutical composition according to claim 4, wherein cellulose-based viscosity agent is a viscosity agent mixture comprising the combination of hydroxypropyl cellulose, carboxymethyl cellulose sodium and carboxymethyl cellulose calcium.
6. The pharmaceutical composition according to claim 1, wherein the diluent is selected from a group comprising calcium carbonate, calcium sulphate, dibasic calcium phosphate, tribasic calcium phosphate, calcium sulphate, microcrystalline cellulose, lactose, magnesium carbonate, magnesium oxide, maltodextrin, maltose, mannitol, sodium chloride, sorbitol, starch, xylitol or combinations thereof.
7. The pharmaceutical composition according to claim 6, wherein lactose is used as diluent.
8. The pharmaceutical composition according to claim 1, wherein said composition further comprises other pharmaceutically acceptable excipients in addition to viscosity agent and diluent that is used together with cefpodoxime proxetil.
9. The pharmaceutical composition according to claim 8, wherein said composition comprises one or more binders, glidant, lubricant, humectant, disintegrant, basic agent, acidic agent, taste regulating agent, flavoring agent and optionally effervescent couple in addition to viscosity agent and diluent that is used together with cefpodoxime proxetil.
10. The pharmaceutical composition according to claim 9, wherein the binder is selected from a group comprising ethyl cellulose, gelatine, hydroxyethyl cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, hypromellose, magnesium duminum silicate, methyl cellulose, povidone or combinations thereof.
11. The pharmaceutical composition according to claim 9, wherein the lubricant is selected from a group comprising calcium stearate, magnesium stearate, polyethylene glycol, PEG 6000, polyvinyl alcohol, potassium benzoate, talc, sodium benzoate or combinations thereof.
12. The pharmaceutical composition according to claim 9, wherein the glidant is selected from a group comprising silicon dioxide, starch, talc, tribasic calcium phosphate or combinations thereof.
13. The pharmaceutical composition according to claim 9, wherein the disintegrant is selected from a group comprising carboxymethyl cellulose calcium, carboxymethylcellulose sodium, silicon dioxide, croscarmellose sodium, crospovidone, hydroxypropyl cellulose, methyl cellulose, povidone, magnesium aluminum silicate, starch or combinations thereof.
14. The pharmaceutical composition according to claim 9, wherein the basic agent is selected from a group comprising potassium carbonate, potassium bicarbonate, potassium citrate, potassium hydroxide, sodium carbonate, sodium bicarbonate or combinations thereof.
15. The pharmaceutical composition according to claim 9, wherein the acidic agent is selected from a group comprising acetic acid, citric acid, lactic acid, malic acid, phosphoric acid, propionic acid, tartaric acid or combinations thereof.
16. The pharmaceutical composition according to claim 15, wherein citric acid is used as acidic agent.
17. The pharmaceutical composition according to claim 9, wherein the taste regulating agent is selected from a group comprising acesulfame, aspartame, dextrose, fructose, glucose, lactitol, maltitol, sorbitol, saccharine sodium, sodium cyclamate, sucralose, sodium chloride, potassium chloride, sucrose, xylitol or combinations thereof.
18. The pharmaceutical composition according to claim 17, wherein saccharose, aspartame, sodium chloride or combinations thereof is used as taste regulating agent.
19. The pharmaceutical composition according to claim 9, wherein the effervescent acid is selected from organic acids such as citric acid, tartaric acid, malic acid, fumaric acid, ascorbic acid, adipic acid and succinic acid.
20. The pharmaceutical composition according to claim 19, wherein citric acid is used as effervescent acid.
21. The pharmaceutical composition according to claim 9, wherein the effervescent base is selected from basic agents such as sodium hydrogen carbonate, sodium carbonate, potassium carbonate, potassium bicarbonate, potassium hydrogen carbonate, sodium glycine carbonate, lysine carbonate, arginine carbonate and calcium carbonate.
22. The pharmaceutical composition according to claim 21, wherein sodium hydrogen carbonate is used as effervescent base.
23. The pharmaceutical composition according to claim 1, wherein said composition comprises cefpodoxime proxetil or its pharmaceutically acceptable solvates, hydrates, enantiomers, racemates, organic salts, inorganic salts, polymorphs, crystal and amorphous forms in an amount equivalent to 5-50% of the unit dose.
24. The pharmaceutical composition according to claim 1, wherein the total amount of one or more viscosity agents used in said composition is 2-15 % with respect to total weight of the unit dose.
25. The pharmaceutical composition according to claim 24, wherein the total amount of one or more viscosity agents used in said composition is 5-12 % with respect to total weight of the unit dose.
26. The pharmaceutical composition according to claim 25, wherein the total amount of one or more viscosity agents used in said composition is 7-10% with respect to total weight of the unit dose.
27. The pharmaceutical composition according to claim 15, wherein the ratio of the acidic agent to cefpodoxime proxetil is in the range of 1 :2 to 1:15.
28. The pharmaceutical composition according to claim 1, wherein said composition comprises 5-50% cefpodoxime proxetil, 0-30% binder, 0.5-4% glidant, 1-7% lubricant, 0-15% disintegrant and/or disintegrants, 1-65% diluent, 1-25% taste regulating agent, 0-20% basic agent, 0.1-25% acidic agent, 2-15% viscosity agent and/or viscosity agents, 0.1-3% flavoring agents and 0-80% effervescent couple with respect to the total amount of unit dose.
29. The process for preparation of a pharmaceutical composition according to the preceding claims, wherein said process comprises granulation of cefpodoxime proxetil through conventional wet and/or dry granulation methods; or dry blending cefpodoxime proxetil and other excipients to obtain a powder and compressing these in tablet compressing machine to obtain tablet forms.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TR2010/02878A TR201002878A2 (en) | 2010-04-13 | 2010-04-13 | Pharmaceutical compositions comprising cefpodoxime proxetil. |
| TR2010/02878 | 2010-04-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2011129792A1 true WO2011129792A1 (en) | 2011-10-20 |
Family
ID=44279055
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/TR2011/000092 WO2011129792A1 (en) | 2010-04-13 | 2011-04-13 | Water dispersible formulations comprising cefpodoxime proxetil |
Country Status (2)
| Country | Link |
|---|---|
| TR (1) | TR201002878A2 (en) |
| WO (1) | WO2011129792A1 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012060786A3 (en) * | 2010-11-05 | 2012-07-26 | Mahmut Bilgic | Cefpodoxime proxetil formulations comprising viscosity agent |
| WO2012026908A3 (en) * | 2010-08-25 | 2012-09-07 | Mahmut Bilgic | Cefpodoxime proxetil formulations comprising taste regulating agent |
| WO2012026907A3 (en) * | 2010-08-25 | 2012-09-13 | Mahmut Bilgic | Cefpodoxime proxetil formulations |
| CN103142506A (en) * | 2013-04-03 | 2013-06-12 | 天津医药集团津康制药有限公司 | Cefpodoxime proxetil granules and preparation method thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0049118A2 (en) | 1980-09-30 | 1982-04-07 | Sankyo Company Limited | Cephalosporin derivatives, their preparation and compositions containing them |
| WO2002067943A1 (en) | 2001-02-27 | 2002-09-06 | Ranbaxy Laboratories Limited | Oral pharmaceutical composition of cefpodoxime proxetil |
| WO2004006917A1 (en) * | 2002-07-16 | 2004-01-22 | Ranbaxy Laboratories Limited | Dispersible tablets for oral administration |
| JP2004043475A (en) * | 2002-07-08 | 2004-02-12 | Sankyo Co Ltd | Oral cephalosporin preparation |
| WO2008057058A1 (en) * | 2006-11-10 | 2008-05-15 | Nobel Ilac Sanayii Ve Ticaret As | Oral pharmaceutical compositions |
-
2010
- 2010-04-13 TR TR2010/02878A patent/TR201002878A2/en unknown
-
2011
- 2011-04-13 WO PCT/TR2011/000092 patent/WO2011129792A1/en active Application Filing
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0049118A2 (en) | 1980-09-30 | 1982-04-07 | Sankyo Company Limited | Cephalosporin derivatives, their preparation and compositions containing them |
| WO2002067943A1 (en) | 2001-02-27 | 2002-09-06 | Ranbaxy Laboratories Limited | Oral pharmaceutical composition of cefpodoxime proxetil |
| JP2004043475A (en) * | 2002-07-08 | 2004-02-12 | Sankyo Co Ltd | Oral cephalosporin preparation |
| WO2004006917A1 (en) * | 2002-07-16 | 2004-01-22 | Ranbaxy Laboratories Limited | Dispersible tablets for oral administration |
| WO2008057058A1 (en) * | 2006-11-10 | 2008-05-15 | Nobel Ilac Sanayii Ve Ticaret As | Oral pharmaceutical compositions |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012026908A3 (en) * | 2010-08-25 | 2012-09-07 | Mahmut Bilgic | Cefpodoxime proxetil formulations comprising taste regulating agent |
| WO2012026907A3 (en) * | 2010-08-25 | 2012-09-13 | Mahmut Bilgic | Cefpodoxime proxetil formulations |
| WO2012060786A3 (en) * | 2010-11-05 | 2012-07-26 | Mahmut Bilgic | Cefpodoxime proxetil formulations comprising viscosity agent |
| WO2012060790A3 (en) * | 2010-11-05 | 2012-09-20 | Mahmut Bilgic | Water dispersible cefpodoxime proxetil formulations |
| CN103142506A (en) * | 2013-04-03 | 2013-06-12 | 天津医药集团津康制药有限公司 | Cefpodoxime proxetil granules and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| TR201002878A2 (en) | 2011-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2528594A2 (en) | Effervescent formulations comprising second generation cephalosporin | |
| US8614315B2 (en) | Cefdinir and cefixime formulations and uses thereof | |
| WO2011129792A1 (en) | Water dispersible formulations comprising cefpodoxime proxetil | |
| WO2011139249A2 (en) | Pharmaceutical composition comprising cefdinir | |
| EP2515850B1 (en) | Pharmaceutical compositions comprising cefdinir as an active agent | |
| WO2011078821A1 (en) | Effervescent tablet and granule formulation comprising cefixime | |
| WO2012060790A2 (en) | Water dispersible cefpodoxime proxetil formulations | |
| EP2608776A2 (en) | Cefpodoxime proxetil formulations | |
| EP2568957A1 (en) | Pharmaceutical composition comprising cefixime and clavulanic acid derivative compound | |
| EP2566449B1 (en) | Pharmaceutical compositions comprising ceftibuten | |
| WO2011093828A2 (en) | Solid dosage forms comprising cefprozil | |
| EP2566451B1 (en) | Pharmaceutical compositions comprising cefditoren pivoxil | |
| EP2515859A1 (en) | Rapidly dispersing effervescent formulation | |
| WO2012060787A1 (en) | Oral dosage forms comprising cefdinir and carboxymethyl cellulose calcium | |
| WO2011139255A2 (en) | Pharmaceutical compositions comprising cefetamet | |
| WO2012060791A2 (en) | Production method for pharmaceutical compositions comprising cefdinir | |
| WO2012060792A1 (en) | Pharmaceutical compositions comprising minimum 6 % of disintegrants by weight | |
| EP2663289A2 (en) | Cefpodoxime proxetil formulations comprising taste regulating agent | |
| WO2012078121A2 (en) | Solid oral dosage form comprising cefdinir | |
| WO2012060789A2 (en) | Production method for cefdinir formulations | |
| EP2833872A1 (en) | Tablet formulations comprising cefpodoxime proxetil and clavulanic acid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11727818 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 11727818 Country of ref document: EP Kind code of ref document: A1 |